Zacks Investment Research upgraded shares of Intellia Therapeutics Inc (NASDAQ:NTLA) from a sell rating to a hold rating in a research note released on Wednesday.

According to Zacks, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Other analysts have also issued research reports about the company. Jefferies Group reaffirmed a buy rating and issued a $33.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, August 17th. Leerink Swann assumed coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued a market perform rating and a $32.00 price target for the company. Wedbush assumed coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an outperform rating and a $38.00 price target for the company. Finally, Credit Suisse Group AG assumed coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an outperform rating and a $39.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $35.50.

Intellia Therapeutics (NASDAQ:NTLA) opened at 19.72 on Wednesday. The stock’s market capitalization is $709.82 million. The company has a 50 day moving average of $19.98 and a 200-day moving average of $22.66. Intellia Therapeutics has a one year low of $17.05 and a one year high of $30.40.

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Institutional Trust Company N.A. purchased a new position in shares of Intellia Therapeutics during the second quarter valued at approximately $1,236,000. BlackRock Fund Advisors bought a new position in shares of Intellia Therapeutics during the second quarter valued at $3,496,000. BlackRock Investment Management LLC bought a new position in shares of Intellia Therapeutics during the second quarter valued at $553,000. BlackRock Advisors LLC bought a new position in shares of Intellia Therapeutics during the second quarter valued at $13,146,000. Finally, Vanguard Group Inc. bought a new position in shares of Intellia Therapeutics during the second quarter valued at $8,894,000.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

5 Day Chart for NASDAQ:NTLA

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.